☆ 4.5 Article

NCCN Guidelines® Insights Neuroendocrine and Adrenal Tumors, Version 2.2018 Featured Updates to the NCCN Guidelines

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)

Journal

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK

Volume 16, Issue 6, Pages 693-702

Publisher

HARBORSIDE PRESS

DOI: 10.6004/jnccn.2018.0056

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Abstract

The NCCN Guidelines for Neuroendocrine and Adrenal Tumors provide recommendations for the management of adult patients with neuroendocrine tumors (NETs), adrenal gland tumors, pheochromocytomas, and paragangliomas. Management of NETs relies heavily on the site of the primary NET. These NCCN Guidelines Insights summarize the management options and the 2018 updates to the guidelines for locoregional advanced disease, and/or distant metastasis originating from gastrointestinal tract, bronchopulmonary, and thymus primary NETs.

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Oncology

Gastrointestinal Stromal Tumors Version 2.2022 Featured Updates to the NCCN Guidelines

Margaret von Mehren, John M. Kane, Richard F. Riedel, Jason K. Sicklick, Seth M. Pollack, Mark Agulnik, Marilyn M. Bui, Janai Carr-Ascher, Edwin Choy, Mary Connelly, Sarah Dry, Kristen N. Ganjoo, Ricardo J. Gonzalez, Ashley Holder, Jade Homsi, Vicki Keedy, Ciara M. Kelly, Edward Kim, David Liebner, Martin McCarter, Sean McGarry, Nathan W. Mesko, Christian Meyer, Alberto S. Pappo, Amanda M. Parkes, Ivy A. Petersen, Matthew Poppe, Scott Schuetze, Jacob Shabason, Matthew B. Spraker, Melissa Zimel, Mary Anne Bergman, Hema Sundar, Lisa E. Hang

Summary: This article introduces the latest guidelines for gastrointestinal stromal tumors (GIST), including treatment options for unresectable, progressive, or metastatic GIST based on mutational status and management recommendations for GIST that develop resistance to specific tyrosine kinase inhibitors.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2022)

Add to Collection

Article Oncology

Palliative Care, Version 2.2021 Featured Updates to the NCCN Guidelines

Maria Dans, Jean S. Kutner, Rajiv Agarwal, Justin N. Baker, Jessica R. Bauman, Anna C. Beck, Toby C. Campbell, Elise C. Carey, Amy A. Case, Shalini Dalal, Danielle J. Doberman, Andrew S. Epstein, Leslie Fecher, Joshua Jones, Jennifer Kapo, Richard T. Lee, Elizabeth T. Loggers, Susan McCammon, William Mitchell, Adeboye B. Ogunseitan, Diane G. Portman, Kavitha Ramchandran, Linda Sutton, Jennifer Temel, Melissa L. Teply, Stephanie Y. Terauchi, Jane Thomas, Anne M. Walling, Finly Zachariah, Mary Anne Bergman, Ndiya Ogba, Mallory Campbell

Summary: Palliative care is increasingly recognized as an integral part of comprehensive cancer care, aiming to improve patient quality of life and outcomes through early intervention. The NCCN Guidelines provide recommendations to help oncology teams promote the best quality of life possible for cancer patients throughout their illness trajectory.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)

Add to Collection

Article Oncology

Survivorship, Version 1.2022 Featured Updates to the NCCN Guidelines

Tara Sanft, Andrew Day, Lindsay Peterson, M. Alma Rodriguez, Shannon Ansbaugh, Saro Armenian, K. Scott Baker, Tarah Ballinger, Gregory Broderick, Wendy Demark-Wahnefried, Kristin Dickinson, Nathan Paul Fairman, Debra L. Friedman, Mindy Goldman, Norah Lynn Henry, Christine Hill-Kayser, Melissa Hudson, Nazanin Khakpour, Divya Koura, Allison L. McDonough, Michelle Melisko, Kathi Mooney, Halle C. F. Moore, Natalie Moryl, Heather Neuman, Tracey O'Connor, Linda Overholser, Electra D. Paskett, Chirayu Patel, William Pirl, Andrea Porpiglia, Kathryn J. Ruddy, Lidia Schapira, Lillie Shockney, Sophia Smith, Karen L. Syrjala, Amye Tevaarwerk, Eric H. Yang, Phyllis Zee, Nicole R. McMillian, Deborah A. Freedman-Cass

Summary: The NCCN Guidelines for Survivorship provide recommendations for addressing the complex needs of cancer survivors, including screening, evaluation, and treatment. They also promote physical activity, weight management, and immunizations, as well as care coordination.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2022)

Add to Collection

Article Oncology

Melanoma: Cutaneous, Version 2.2021 Featured Updates to the NCCN Guidelines

Susan M. Swetter, John A. Thompson, Mark R. Albertini, Christopher A. Barker, Joel Baumgartner, Genevieve Boland, Bartosz Chmielowski, Dominick DiMaio, Alison Durham, Ryan C. Fields, Martin D. Fleming, Anjela Galan, Brian Gastman, Kenneth Grossmann, Samantha Guild, Ashley Holder, Douglas Johnson, Richard W. Joseph, Giorgos Karakousis, Kari Kendra, Julie R. Lange, Ryan Lanning, Kim Margolin, Anthony J. Olszanski, Patrick A. Ott, Merrick Ross, April K. Salama, Rohit Sharma, Joseph Skitzki, Jeffrey Sosman, Evan Wuthrick, Nicole R. McMillian, Anita M. Engh

Summary: In recent years, the NCCN Guidelines for Melanoma: Cutaneous have expanded to include pathways for microscopic satellitosis, molecular testing, systemic therapy considerations, and brain metastases management. The latest update in v1.2021 includes additional modifications to pathology, surgical margins, lymph node biopsy, lymph node dissection, and radiation therapy recommendations.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)

Add to Collection

Article Oncology

Hodgkin Lymphoma, Version 2.2022 Featured Updates to the NCCN Guidelines

Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Philippe Armand, Celeste M. Bello, Cecil M. Benitez, Weina Chen, Bouthaina Dabaja, Megan E. Daly, Leo I. Gordon, Neil Hansen, Alex F. Herrera, Ephraim P. Hochberg, Patrick B. Johnston, Mark S. Kaminski, Christopher R. Kelsey, Vaishalee P. Kenkre, Nadia Khan, Ryan C. Lynch, Kami Maddocks, Jonathan McConathy, Monika Metzger, David Morgan, Carolyn Mulroney, Sheeja T. Pullarkat, Rachel Rabinovitch, Karen C. Rosenspire, Stuart Seropian, Randa Tao, Pallawi Torka, Jane N. Winter, Joachim Yahalom, Joanna C. Yang, Jennifer L. Burns, Mallory Campbell, Hema Sundar

Summary: This article discusses the classification and treatment options for Hodgkin lymphoma, focusing on radiation therapy dose constraints and the management of advanced-stage and relapsed or refractory Hodgkin lymphoma.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2022)

Add to Collection

Article Oncology

Survivorship, Version 1.2023 Featured Updates to the NCCN Guidelines

Tara Sanft, Andrew Day, Shannon Ansbaugh, Saro Armenian, K. Scott Baker, Tara Ballinger, Wendy Demark-Wahnefried, Kristin Dickinson, Nathan Paul Fairman, Josephine Felciano, Tessa Faye Flores, Debra L. Friedman, Nicolette M. Gabel, Mindy Goldman, Norah Lynn Henry, Christine Hill-Kayser, Melissa Hudson, Divya Koura, Kimberly Lee, Allison L. Mcdonough, Michelle Melisko, Kathi Mooney, Halle C. F. Moore, Natalie Moryl, Heather Neuman, Tracey O'Connor, Linda Overholser, Electra D. Paskett, Chirayu Patel, Lindsay Peterson, William Pirl, Andrea Porpiglia, M. Alma Rodriguez, Lidia Schapira, Anna L. Schwartz, Sophia Smith, Amye Tevaarwerk, Eric Yang, Phyllis Zee, Nicole R. McMillian, Deborah A. Freedman-Cass

Summary: The NCCN Guidelines for Survivorship assist healthcare professionals in addressing the diverse needs of cancer survivors. These guidelines offer recommendations for screening, evaluation, and treatment of psychosocial and physical issues resulting from cancer and its treatment, as well as promoting healthy behaviors and immunizations. The guidelines also provide a framework for care coordination.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2023)

Add to Collection

Article Oncology

Survivorship, Version 1.2021 Featured Updates to the NCCN Guidelines

Amye Tevaarwerk, Crystal S. Denlinger, Tara Sanft, Shannon M. Ansbaugh, Saro Armenian, K. Scott Baker, Gregory Broderick, Andrew Day, Wendy Demark-Wahnefried, Kristin Dickinson, Debra L. Friedman, Patricia Ganz, Mindy Goldman, Norah Lynn Henry, Christine Hill-Kayser, Melissa Hudson, Nazanin Khakpour, Divya Koura, Allison L. McDonough, Michelle Melisko, Kathi Mooney, Halle C. F. Moore, Natalie Moryl, Javid J. Moslehi, Tracey O'Connor, Linda Overholser, Electra D. Paskett, Chirayu Patel, Lindsay Peterson, William Pirl, M. Alma Rodriguez, Kathryn J. Ruddy, Lidia Schapira, Lillie Shockney, Sophia Smith, Karen L. Syrjala, Phyllis Zee, Nicole R. McMillian, Deborah A. Freedman-Cass

Summary: The NCCN Guidelines for Survivorship aim to assist healthcare professionals in meeting the complex needs of cancer survivors, including recommendations for employment and return to work.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)

Add to Collection

Article Oncology

Older Adult Oncology, Version 1.2021 Featured Updates to the NCCN Guidelines

Efrat Dotan, Louise C. Walter, Ilene S. Browner, Katherine Clifton, Harvey Jay Cohen, Martine Extermann, Cary Gross, Sumati Gupta, Genevieve Hollis, Joleen Hubbard, Reshma Jagsi, Nancy L. Keating, Elizabeth Kessler, Thuy Koll, Beatriz Korc-Grodzicki, June M. McKoy, Sumi Misra, Dominic Moon, Tracey O'Connor, Cynthia Owusu, Ashley Rosko, Marcia Russell, Mina Sedrak, Fareeha Siddiqui, Amy Stella, Derek L. Stirewalt, Ishwaria M. Subbiah, William P. Tew, Grant R. Williams, Liz Hollinger, Giby George, Hema Sundar

Summary: The NCCN Guidelines for Older Adult Oncology address specific issues related to cancer management in older adults, with a focus on comprehensive geriatric assessment (CGA) as a multidisciplinary evaluation method to assess health status and various domains relevant to cancer treatment choices. Recent updates to the guidelines provide a specific practical framework for using CGA in evaluating older adults with cancer.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)

Add to Collection

Article Oncology

Hematopoietic Cell Transplantation, Version 3.2022 Featured Updates to the NCCN Guidelines

Ayman Saad, Alison Loren, Javier Bolanos-Meade, George Chen, Daniel Couriel, Antonio Di Stasi, Areej El-Jawahri, Hany Elmariah, Sherif Farag, Krishna Gundabolu, Jonathan Gutman, Vincent Ho, Rasmus Hoeg, Mitchell Horwitz, Joe Hsu, Adetola Kassim, Mohamed Kharfan Dabaja, John Magenau, Thomas Martin, Marco Mielcarek, Jonathan Moreira, Ryotaro Nakamura, Yago Nieto, Cameron Ninos, Caspian Oliai, Seema Patel, Brion Randolph, Mark Schroeder, Dimitrios Tzachanis, Asya Nina Varshavsky-Yanovsky, Madhuri Vusirikala, Frankie Algieri, Lenora A. Pluchino

Summary: The NCCN Guidelines provide evidence-based recommendations for hematopoietic cell transplantation in adult patients with malignant diseases. These guidelines cover various aspects of transplantation, including recipient evaluation, cell mobilization, and treatment of graft-versus-host disease, aiming to assist patients and clinicians in making informed decisions.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2023)

Add to Collection

Article Oncology

Hematopoietic Growth Factors, Version 1.2022 Featured Updates to the NCCN Guidelines

Elizabeth A. Griffiths, Vivek Roy, Laura Alwan, Kimo Bachiashvili, John Baird, Rita Cool, Shira Dinner, Mark Geyer, John Glaspy, Ivana Gojo, Ashley Hicks, Avyakta Kallam, Wajih Zaheer Kidwai, Dwight D. Kloth, Eric H. Kraut, Daniel Landsburg, Gary H. Lyman, Anjlee Mahajan, Ryan Miller, Victoria Nachar, Seema Patel, Shiven Patel, Lia E. Perez, Adam Poust, Fauzia Riaz, Rachel Rosovsky, Hope S. Rugo, Shayna Simon, Sumithira Vasu, Martha Wadleigh, Kelly Westbrook, Peter Westervelt, Ryan A. Berardi, Lenora Pluchino

Summary: The NCCN Guidelines provide recommendations for the appropriate use of growth factors in the management of certain conditions in adult patients with nonmyeloid malignancies. The guidelines aim to evaluate, prevent, and treat febrile neutropenia, chemotherapy-induced thrombocytopenia, and chemotherapy-induced anemia, allowing patients and clinicians to assess management options based on individual patient's condition. The recent updates emphasize the incorporation of a newly developed section on chemotherapy-induced thrombocytopenia.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2022)

Add to Collection

Article Oncology

Prostate Cancer, Version 1.2023 Featured Updates to the NCCN Guidelines

Edward M. Schaeffer, Sandy Srinivas, Nabil Adra, Yi An, Daniel Barocas, Rhonda Bitting, Alan Bryce, Brian Chapin, Heather H. Cheng, Anthony Victor D'Amico, Neil Desai, Tanya Dorff, James A. Eastham, Thomas A. Farrington, Xin Gao, Shilpa Gupta, Thomas Guzzo, Joseph E. Ippolito, Michael R. Kuettel, Joshua M. Lang, Tamara Lotan, Rana R. McKay, Todd Morgan, George Netto, Julio M. Pow-Sang, Robert Reiter, Mack Roach, Tyler Robin, Stan Rosenfeld, Ahmad Shabsigh, Daniel Spratt, Benjamin A. Teply, Jonathan Tward, Richard Valicenti, Jessica Karen Wong, Ryan A. Berardi, Dorothy A. Shead, Deborah A. Freedman-Cass

Summary: The NCCN Guidelines for Prostate Cancer discuss staging and risk assessment after a prostate cancer diagnosis and provide treatment options for different stages of the disease. The guidelines are updated annually based on new clinical data and input from various sources. This article summarizes the discussions regarding systemic therapy for metastatic prostate cancer.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2022)

Add to Collection

Article Oncology

Myelodysplastic Syndromes, Version 3.2022 Featured Updates to the NCCN Guidelines

Peter L. Greenberg, Richard M. Stone, Aref Al-Kali, John M. Bennett, Uma Borate, Andrew M. Brunner, Wanxing Chai-Ho, Peter Curtin, Carlos M. de Castro, H. Joachim Deeg, Amy E. DeZern, Shira Dinner, Charles Foucar, Karin Gaensler, Guillermo Garcia-Manero, Elizabeth A. Griffiths, David Head, Brian A. Jonas, Sioban Keel, Yazan Madanat, Lori J. Maness, James Mangan, Shannon McCurdy, Christine McMahon, Bhumika Patel, Vishnu V. Reddy, David A. Sallman, Rory Shallis, Paul J. Shami, Swapna Thota, Asya Nina Varshavsky-Yanovsky, Peter Westervelt, Elizabeth Hollinger, Dorothy A. Shead, Cindy Hochstetler

Summary: The NCCN Guidelines for Myelodysplastic Syndromes (MDS) provide recommendations for the evaluation, diagnosis, and management of patients with MDS based on clinical evidence. The 2022 updates include treatment recommendations for both lower-risk and higher-risk MDS, emerging therapies, supportive care recommendations, and genetic assessment for hereditary myeloid malignancy predisposition syndromes.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2022)

Add to Collection

Article Oncology

Multiple Myeloma, Version 3.2022 Featured Updates to the NCCN Guidelines

Natalie S. Callander, Muhamed Baljevic, Kehinde Adekola, Larry D. Anderson, Erica Campagnaro, Jorge J. Castillo, Caitlin Costello, Srinivas Devarakonda, Noura Elsedawy, Matthew Faiman, Alfred Garfall, Kelly Godby, Jens Hillengass, Leona Holmberg, Myo Htut, Carol Ann Huff, Malin Hultcrantz, Yubin Kang, Sarah Larson, Michaela Liedtke, Thomas Martin, James Omel, Douglas Sborov, Kenneth Shain, Keith Stockerl-Goldstein, Donna Weber, Ryan A. Berardi, Rashmi Kumar, Shaji K. Kumar

Summary: The NCCN Guidelines for Multiple Myeloma offer recommendations for various aspects of diagnosis, initial workup, treatment, follow-up, and supportive care for patients. The 2022 version of the guidelines highlights important updates/changes specifically related to the treatment of multiple myeloma patients.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2022)

Add to Collection

Article Oncology

Breast Cancer, Version 4.2021 Featured Updates to the NCCN Guidelines

William J. Gradishar, Meena S. Moran, Jame Abraham, Rebecca Aft, Doreen Agnese, Kimberly H. Allison, Sarah L. Blair, Harold J. Burstein, Chau Dang, Anthony D. Elias, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Sara A. Hurvitz, Steven J. Isakoff, Rachel C. Jankowitz, Sara H. Javid, Jairam Krishnamurthy, Marilyn Leitch, Janice Lyons, Jennifer Matro, Ingrid A. Mayer, Joanne Mortimer, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Hope S. Rugo, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, Erica M. Stringer-Reasor, Melinda L. Telli, John H. Ward, Kari B. Wisinski, Jessica S. Young, Jennifer L. Burns, Rashmi Kumar

Summary: The NCCN Guidelines for Breast Cancer cover various types of breast cancer and are developed by a multidisciplinary panel of experts. The recent updates focus on recommendations for adjuvant systemic therapy in patients with early-stage, hormone receptor-positive, HER2-negative breast cancer.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)

Add to Collection

Article Oncology

Bladder Cancer, Version 2.2022 Featured Updates to the NCCN Guidelines

Thomas W. Flaig, Philippe E. Spiess, Michael Abern, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Kevin Chan, Sam Chang, Terence Friedlander, Richard E. Greenberg, Khurshid A. Guru, Harry W. Herr, Jean Hoffman-Censits, Amar Kishan, Shilajit Kundu, Subodh M. Lele, Ronac Mamtani, Vitaly Margulis, Omar Y. Mian, Jeff Michalski, Jeffrey S. Montgomery, Lakshminarayanan Nandagopal, Lance C. Pagliaro, Mamta Parikh, Anthony Patterson, Elizabeth R. Plimack, Kamal S. Pohar, Mark A. Preston, Kyle Richards, Wade J. Sexton, Arlene O. Siefker-Radtke, Matthew Tollefson, Jonathan Tward, Jonathan L. Wright, Mary A. Dwyer, Carly J. Cassara, Lisa A. Gurski

Summary: This article discusses the importance of the NCCN Guidelines for Bladder Cancer, as well as recent updates and panel discussions regarding the treatment of non-muscle-invasive bladder cancer.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2022)

Add to Collection

Article Materials Science, Biomaterials

Understanding Suboptimal Response to Immune Checkpoint Inhibitors

Mojun Zhu, Henan Zhang, Katrina S. Pedersen, Nathan R. Foster, Brandy L. Jaszewski, Xin Liu, Jacob B. Hirdler, Zesheng An, Tanios S. Bekaii-Saab, Thorvardur R. Halfdanarson, Patrick M. Boland, Yiyi Yan, Joleen H. Hubbard, Wen Wee Ma, Harry H. Yoon, Alexander Revzin, Martin E. Fernandez-Zapico, Michael J. Overman, Robert R. McWilliams, Haidong Dong

Summary: Immune checkpoint inhibitors (ICIs) have shown promise as a novel class of anticancer therapy, but their clinical efficacy is limited to certain tumor types. This study aimed to understand the treatment response to an ICI targeting programmed death-1 in patients with small bowel adenocarcinoma. The findings suggest that the frequency and cytolytic capacity of circulating immune cells may differentiate clinical response to ICIs, providing a basis for immune monitoring using patient peripheral blood.

ADVANCED BIOLOGY (2023)

Add to Collection

Review Pathology

Primary neuroendocrine tumors and primary neuroendocrine carcinomas of the liver: a proposal for a multidiscipline definition

Michael Torbenson, Sudhakar K. Venkatesh, Thorvardur R. Halfdanarson, Patrick J. Navin, Patrick Kamath, Lori A. Erickson

Summary: Primary hepatic neuroendocrine tumors and primary hepatic neuroendocrine carcinomas are rare and challenging to diagnose if they are primary to the liver or metastatic. The lack of a uniform definition for primary hepatic neuroendocrine neoplasms hinders understanding and treatment of these rare tumors. This article proposes a multidisciplinary definition and guidelines for diagnosing a neuroendocrine tumor/neuroendocrine carcinomas as being primary to the liver.

HUMAN PATHOLOGY (2023)

Add to Collection

Article Oncology

Mixed Acinar Neuroendocrine Carcinoma of the Pancreas: Comparative Population-Based Epidemiology of a Rare and Fatal Malignancy in The United States

Amro M. Abdelrahman, Jun Yin, Roberto Alva-Ruiz, Jennifer A. Yonkus, Jennifer L. Leiting, Isaac T. Lynch, Alessandro Fogliati, Nellie A. Campbell, Danielle M. Carlson, Lewis R. Roberts, Gregory J. Gores, Rory L. Smoot, Rondell P. Graham, Thorvardur R. Halfdanarson, Mark J. Truty

Summary: Mixed acinar neuroendocrine carcinoma of the pancreas (MANEC-P) is an extremely rare and aggressive malignancy. This study aimed to estimate and compare the incidence, prevalence, and cancer-specific survival of MANEC-P in the United States. The results showed a steady incidence rate of MANEC-P over the last two decades, with a poor prognosis and being the 5th leading cause of pancreatic cancer-related death in the US.

CANCERS (2023)

Add to Collection

Editorial Material Oncology

ASO Visual Abstract: Survival and Symptomatic Relief After Cytoreductive Hepatectomy for Neuroendocrine Tumor Liver Metastases-Long-Term Follow-Up of Over 500 Patients

Hallbera Gudmundsdottir, Elizabeth B. Habermann, Robert A. Vierkant, Patrick Starlinger, Cornelius A. Thiels, Susanne G. Warner, Rory L. Smoot, Mark J. Truty, Michael L. Kendrick, Thorvardur R. Halfdanarson, David M. Nagorney, Sean P. Cleary

ANNALS OF SURGICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Survival and Symptomatic Relief After Cytoreductive Hepatectomy for Neuroendocrine Tumor Liver Metastases: Long-Term Follow-up Evaluation of More Than 500 Patients

Hallbera Gudmundsdottir, Elizabeth R. B. Habermann, Robert A. A. Vierkant, Patrick Starlinger, Cornelius A. A. Thiels, Susanne G. G. Warner, Rory L. L. Smoot, Mark J. J. Truty, Michael L. L. Kendrick, Thorvardur R. R. Halfdanarson, David M. M. Nagorney, Sean P. P. Cleary

Summary: This retrospective analysis examined patients who underwent cytoreductive hepatectomy for liver metastases from neuroendocrine tumors. The study found that the surgery can relieve symptoms and prolong survival, with low morbidity and mortality rates. It also showed that functional tumors can achieve durable symptomatic relief.

ANNALS OF SURGICAL ONCOLOGY (2023)

Add to Collection

Article Endocrinology & Metabolism

Efficacy of first-line checkpoint inhibitors in combination with chemotherapy in high-grade extrapulmonary metastatic neuroendocrine carcinomas

Jennifer J. Gile, Patrick W. McGarrah, Konstantinos Leventakos, Mohamad B. Sonbol, Jason S. Starr, Rachel A. Eiring, Timothy J. Hobday, Thorvardur R. Halfdanarson

Summary: Poorly differentiated extrapulmonary neuroendocrine carcinomas (EP NECs) are aggressive cancers. EP NECs are typically treated with platinum-based regimens, and some clinicians have added a checkpoint inhibitor (CPI) to the treatment based on data from trials in patients with small cell carcinoma of the lung. However, a retrospective study did not find any additional benefit of adding CPI to the standard chemotherapy in EP NECs.

JOURNAL OF NEUROENDOCRINOLOGY (2023)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Evaluation of Hepatotoxicity from Peptide Receptor Radionuclide Therapy in Patients with Gastroenteropancreatic Neuroendocrine Tumors and a Very High Liver Tumor Burden

Denise A. Gococo-Benore, Justin Kuhlman, Ephraim E. Parent, Akash Sharma, Joseph Accurso, Ming Yang, Ayse Tuba Kendi, Geoff Johnson, Mohamad Bassam Sonbol, Timothy Hobday, Thorvardur R. Halfdanarson, Jason Starr

Summary: The aim of this study was to assess the risk of liver toxicity in patients with gastroenteropancreatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy (PRRT) with a very high liver tumor burden. The results showed that only one out of fifteen patients with more than 75% liver involvement experienced liver function deterioration, with no clinical signs of liver failure. Therefore, PRRT may be considered a safe option for patients with extensive liver involvement.

JOURNAL OF NUCLEAR MEDICINE (2023)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Clinical utility of somatostatin receptor positron emission tomography imaging biomarkers for characterization of meningioma among incidental central nervous system lesions

Shannon Fortin Ensign, Muskan Agarwal, Molly Klanderman, Mohamed Badawy, Thorvardur R. Halfdanarson, Derek R. Johnson, Mohamad Bassam Sonbol, Ayse T. Kendi

Summary: Ga-68-DOTATATE PET imaging can accurately differentiate CNS lesions, particularly meningiomas. Increased avidity on PET scans is more indicative of meningiomas, while low SUV cases may have more varied predictions.

NUCLEAR MEDICINE COMMUNICATIONS (2023)

Add to Collection

Letter Oncology

Reply to Residual Tumor Volume, Not Percent Cytoreduction, Matters for Surgery of Neuroendocrine Liver Metastasis

Hallbera Gudmundsdottir, Sean P. Cleary, Thorvardur R. Halfdanarson

ANNALS OF SURGICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Accuracy of DOTATATE PET imaging in the preoperative planning of small bowel neuroendocrine tumor resection

Chi Zhang, Hallbera Gudmundsdottir, Hiroaki Takahashi, Courtney Day, Amy Glasgow, Nabil Wasif, Patrick Starlinger, Susanne Warner, Travis Grotz, Rory Smoot, Mark Truty, Sean Cleary, Michael Kendrick, David Nagorney, Patrick Navin, Thorvardur R. Halfdanarson, Cornelius Thiels

Summary: The accuracy of preoperative gallium-68 DOTA-Tyr3-octreotate (DOTATATE) positron emission tomography (PET) imaging in estimating multifocality and nodal metastases of small bowel neuroendocrine tumors (sbNETs) was assessed. The sensitivity and negative predictive value (NPV) of DOTATATE PET imaging were found to be insufficient to guide surgical planning.

JOURNAL OF SURGICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

COVID-19 severity and cardiovascular outcomes in SARS-CoV-2-infected patients with cancer and cardiovascular disease

Melissa Y. Y. Moey, Cassandra Hennessy, Benjamin French, Jeremy L. Warner, Matthew D. Tucker, Daniel J. Hausrath, Dimpy P. Shah, Jeanne M. DeCara, Ziad Bakouny, Chris Labaki, Toni K. Choueiri, Susan Dent, Nausheen Akhter, Roohi Ismail-Khan, Lisa Tachiki, David Slosky, Tamar S. Polonsky, Joy A. Awosika, Audrey Crago, Trisha Wise-Draper, Nino Balanchivadze, Clara Hwang, Leslie A. Fecher, Cyndi Gonzalez Gomez, Brandon Hayes-Lattin, Michael J. Glover, Sumit A. Shah, Dharmesh Gopalakrishnan, Elizabeth A. Griffiths, Daniel H. Kwon, Vadim S. Koshkin, Sana Mahmood, Babar Bashir, Taylor Nonato, Pedram Razavi, Rana R. McKay, Gayathri Nagaraj, Eric Oligino, Matthew Puc, Polina Tregubenko, Elizabeth M. Wulff-Burchfield, Zhuoer Xie, Thorvardur R. Halfdanarson, Dimitrios Farmakiotis, Elizabeth J. Klein, Elizabeth V. Robilotti, Gregory J. Riely, Jean-Bernard Durand, Salim S. Hayek, Lavanya Kondapalli, Stephanie Berg, Timothy E. O'Connor, Mehmet A. Bilen, Cecilia Castellano, Melissa K. Accordino, Blau Sibel, Lisa B. Weissmann, Chinmay Jani, Daniel B. Flora, Lawrence Rudski, Miriam Santos Dutra, Bouganim Nathaniel, Erika Ruiz-Garcia, Diana Vilar-Compte, Shilpa Gupta, Alicia Morgans, Anju Nohria

Summary: This retrospective cohort study found that cancer patients with co-morbid cardiovascular disease/risk factors had higher COVID-19 severity and were more likely to experience adverse cardiovascular events. The association between co-morbid cardiovascular disease/risk factors and COVID-19 severity was stronger in patients not receiving active cancer therapy.

TRANSLATIONAL ONCOLOGY (2023)

Add to Collection

Review Oncology

Managing Metastatic Extrapulmonary Neuroendocrine Carcinoma After First-Line Treatment

Nikolaos Andreatos, Patrick W. W. McGarrah, Mohamad Bassam Sonbol, Jason S. S. Starr, Jaume Capdevila, Halfdan Sorbye, Thorvardur R. R. Halfdanarson

Summary: This review evaluates the second-line and later therapeutic options for extrapulmonary neuroendocrine carcinoma (EP-NEC) and explores potential future developments. Promising regimens, such as systemic therapy combinations and novel checkpoint inhibitors, are gradually being utilized in the second-line setting. Advances in understanding disease biology are also helping to refine patient selection and identify targeted therapy options. While there are still many questions to be answered, contemporary developments provide grounds for optimism regarding improved outcomes for EP-NEC.

CURRENT ONCOLOGY REPORTS (2023)

Add to Collection

Review Oncology

Monitoring and Surveillance of Patients with Gastroenteropancreatic Neuroendocrine Tumors Undergoing Radioligand Therapy

Thorvardur R. Halfdanarson, Nadine Mallak, Scott Paulson, Chandrikha Chandrasekharan, Mona Natwa, Ayse Tuba Kendi, Hagen F. Kennecke

Summary: This article discusses the best practices in radioligand therapy for GEP-NETs patients, including imaging, clinical biochemistry, and tumor assessment criteria. Effective monitoring and surveillance measures are crucial for personalized clinical decision-making in individual clinical circumstances.

CANCERS (2023)

Add to Collection

Review Biology

Combination Systemic Therapies in Advanced Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): A Comprehensive Review of Clinical Trials and Prospective Studies

Leonidas N. Diamantopoulos, Markos Kalligeros, Thorvardur R. Halfdanarson, Nikolaos Diamantis, Christos Toumpanakis

Summary: There are various systemic combination regimens being investigated for advanced well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This review provides an overview of the clinical trials and prospective studies on combination treatments. Results show a wide range of efficacy in reported combinations, and only a few phase 3 trials have shown practice-changing results. Peptide receptor radionuclide therapy (PRRT)-based combinations and anti-vascular endothelial growth factor (VEGF) agent combinations with standard chemotherapy have shown promising results, while immune-checkpoint inhibitor-based combinations have limited applicability.

BIOLOGY-BASEL (2023)

Add to Collection

Letter Oncology

Omitting hemicolectomy for patients with appendiceal neuroendocrine tumours of 1-2 cm

Thorvardur R. Halfdanarson, Travis E. Grotz, Hallbera Gudmundsdottir, Sean P. Cleary

LANCET ONCOLOGY (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.